✦ LIBER ✦

An open randomised trial of second-line endocrine therapy in advanced breast cancer: comparison of the aromatase inhibitors letrozole and anastrozole

✍ Scribed by C. Rose; O. Vtoraya; A. Pluzanska; N. Davidson; M. Gershanovich; R. Thomas; S. Johnson; J.J. Caicedo; H. Gervasio; G. Manikhas; F. Ben Ayed; S. Burdette-Radoux; H.A. Chaudri-Ross; R. Lang

Book ID: 117660212
Publisher: Elsevier Science
Year: 2003
Tongue: English
Weight: 213 KB
Volume: 39
Category: Article
ISSN: 0959-8049
DOI: 10.1016/s0959-8049(03)00630-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

An open randomised trial of second-line

An open randomised trial of second-line endocrine therapy in advanced breast cancer: comparison of the Aromatase inhibitors letrozole and anastrozole

✍ J.S Tobias; A Howell 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 122 KB

A comparison of fulvestrant and the thir

A comparison of fulvestrant and the third-generation aromatase inhibitors in the second-line treatment of postmenopausal women with advanced breast cancer

✍ David Dodwell; Ignace Vergote 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 317 KB

New aromatase inhibitors as second-line

New aromatase inhibitors as second-line endocrine therapy in postmenopausal patients with metastatic breast carcinoma : A pooled analysis of the randomized trials

✍ Paolo Carlini; Emilio Bria; Diana Giannarelli; Gianluigi Ferretti; Alessandra Fe 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 224 KB 👁 2 views

Combined use of goserelin (zoladex) and

Combined use of goserelin (zoladex) and anastrozole (arimidex) as second-line endocrine therapy in premenopausal women with advanced breast cancer — a study of its clinical and endocrine effects

✍ K.L. Cheung; D.P. Forward; L. Jackson; J.F.R. Robertson 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 135 KB

68. Randomized trial between the selecti

68. Randomized trial between the selective aromatase inhibitor formestane (Lentaron) or tamoxifen as first-line hormonal therapy in postmenopausal patients with advanced breast cancer: confirmation of bioequivalence in survival

✍ C.M. Royce; L. Mauriac; R. Pérez Carrion; V. Alberola; F. Calabresi; R.Th. Miche 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 148 KB

The combination of letrozole and trastuz

The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers

✍ P. Kelly Marcom; Claudine Isaacs; Lyndsay Harris; Zee Wang Wong; Aruna Kommarred 📂 Article 📅 2006 🏛 Springer US 🌐 English ⚖ 144 KB